CerroZone™ Reduces Airborne COVID-19 Delta Variant by 99.998% in Approximately 1.2 Seconds

CerroZone™ Reduces Airborne COVID-19 Delta Variant by 99.998% in Approximately 1.2 Seconds




CerroZone™ Reduces Airborne COVID-19 Delta Variant by 99.998% in Approximately 1.2 Seconds

Air Purification System Achieves Intertek™ Zero Ozone Certification

CHICAGO–(BUSINESS WIRE)–The new CerroZone™ indoor air purification system achieved a 99.998 percent reduction of live COVID-19 Delta Variant in a single pass of approximately 1.2 seconds, according to independent testing at MRI Global in Kansas City. The report will be published in the coming weeks on the CerroZone website.

Additionally, CerroZone has achieved and surpassed the standard for Intertek’s Zero Ozone Certification. Intertek considers emissions of .005 ppm or less to be negligible per UL 2998, the industry standard for ozone testing in North America. CerroZone recorded at .001 ppm or over 80 percent less than the threshold to be considered “Zero Ozone” certified.

“Today’s news validates our confidence in the exceptional quality of our system,” commented Marlon Robinson, Director of Operations for CerroZone. “We knew the effectiveness of the CerroZone unit based on our prior testing, including on live COVID-19, so to show similar effectiveness on a different strain reinforces that CerroZone is positioned to aid the public in the fight against emerging and future variants.”

“We are also thrilled our patent-pending technology, which harnesses the natural power of ozone, has shown that all ozone is safely contained within our devices, and, in fact, we meet and surpass the industry standard of ‘Zero Ozone’ established by Intertek,” Robinson added. “This is a reminder that CerroZone is an air purification technology designed with consumer health and environmental safety in mind.”

Developed in response to the global COVID-19 pandemic, the CerroZone mobile unit helps purify air in buildings such as schools, houses of worship, offices, and other indoor spaces.

CerroZone has applied under Section 510(k) of the Food, Drug and Cosmetic Act, which requires device manufacturers to notify the FDA of their intent to market a medical device at least 90 days before launching the product. The company plans to manufacture and ship units beginning in the second half of 2022.

The patent-pending system was developed in conjunction with Micron Pure™, a Hecto Group™ company.

Details and updates will be shared on www.CerroZone.com.

CerroZone is part of the Marmon Plumbing & Refrigeration group of Chicago-based Marmon Holdings, Inc. Marmon Holdings, a Berkshire Hathaway company, is a global industrial organization comprising 11 diverse business groups and more than 100 autonomous manufacturing and service businesses.

For additional information, contact: sales@cerrozone.com or visit www.CerroZone.com

Contacts

Michael Duggan at michael.duggan@marmon.com